OPEP therapy: Is your current mucus clearance falling short?

Written by The Life Science Feed Editorial Team · Published 7 September 2026 · Edited by Mara Voss

> Effective mucus clearance remains a cornerstone of respiratory disease management, yet achieving it consistently across diverse patient populations presents an ongoing challenge. Oscillating positive expiratory pressure (OPEP) therapy provides a mechanical, non-pharmacological intervention designed to address this persistent clinical need, offering a practical tool for improving airway hygiene.

KEY TAKEAWAYS

- The Pivot: OPEP therapy integrates into existing care pathways, offering a scalable solution for chronic mucus retention.
- The Data: OPEP devices enhance sputum expectoration and improve lung function parameters in multiple respiratory conditions.
- The Action: Clinicians should consider OPEP therapy as an adjunct to standard care for patients with chronic productive cough or impaired mucociliary clearance.

Chronic respiratory conditions often share a common, debilitating feature: impaired mucociliary clearance, leading to mucus accumulation, airway obstruction, and recurrent infections. This cycle perpetuates inflammation and structural lung damage, significantly impacting patient quality of life and increasing healthcare burden. Conditions such as cystic fibrosis (CF), bronchiectasis, chronic obstructive pulmonary disease (COPD), and even asthma with significant mucus plugging, all benefit from strategies that facilitate the removal of tenacious secretions. Standard approaches include bronchodilators, mucolytics, and various chest physiotherapy techniques, but these often require significant patient effort or specialized equipment. The need for accessible, effective, and patient-friendly mucus management tools is clear. Oscillating positive expiratory pressure (OPEP) devices represent a class of airway clearance techniques that combine positive expiratory pressure with high-frequency oscillations. These devices are designed to dislodge mucus from airway walls, move it centrally, and facilitate its expectoration. The mechanism involves creating a positive pressure during exhalation, which helps to stent open airways and prevent collapse, particularly in patients with dynamic airway compression. Simultaneously, the oscillations, generated by a resistor or a flutter valve, transmit kinetic energy into the airways, shearing mucus from the bronchial walls and reducing its viscosity. This dual action aims to improve the rheological properties of mucus and enhance its transport out of the lungs. The simplicity and portability of OPEP devices make them attractive for home use, promoting patient independence and adherence to therapy.

The Mechanics of Mucus Clearance

Understanding the physiological basis of OPEP therapy is important for its effective integration into clinical practice. Normal mucociliary clearance relies on the coordinated beating of cilia, which propel a thin layer of mucus towards the pharynx for swallowing or expectoration. In many chronic lung diseases, this delicate system is compromised. Ciliary dysfunction, increased mucus production, and altered mucus rheology (e.g., increased viscosity and elasticity) all contribute to impaired clearance. OPEP devices counteract these deficits by mechanically assisting mucus movement. The positive expiratory pressure helps to maintain airway patency, especially in smaller airways that might otherwise collapse during forced exhalation. This allows air to get behind trapped mucus, facilitating its movement. The oscillations, typically in the range of 6-20 Hz, create a vibratory effect that loosens mucus attachments and reduces its viscoelasticity, making it easier to cough up. This combination of pressure and vibration is distinct from other airway clearance methods, such as postural drainage or directed cough, offering a unique therapeutic profile.

The application of OPEP therapy is generally straightforward, requiring minimal training for patients. Patients exhale actively but not forcefully into the device, creating the positive pressure and oscillations. Sessions typically last 10-20 minutes, performed once or twice daily, or more frequently during exacerbations. Proper technique involves maintaining a tight seal around the mouthpiece, controlling exhalation, and performing huff coughs periodically to clear mobilized secretions. Device selection often depends on patient preference, lung capacity, and the specific resistance required to achieve optimal oscillations. Some devices offer adjustable resistance, allowing for personalization of therapy. Regular review of technique by a physiotherapist or respiratory nurse is essential to ensure efficacy and prevent misuse. For a comprehensive overview of respiratory conditions and their management, clinicians might consult the Oxford Handbook of Respiratory Medicine.

Clinical Applications Across Respiratory Diseases

OPEP therapy has found utility across a spectrum of respiratory conditions where mucus retention is a significant problem. In cystic fibrosis, OPEP devices are a well-established component of airway clearance regimens. Patients with CF produce thick, sticky mucus that obstructs airways, leading to chronic infection and inflammation. OPEP therapy, often used in conjunction with nebulized mucolytics and bronchodilators, helps to mobilize these tenacious secretions, reducing exacerbation frequency and improving lung function. The portability of OPEP devices is particularly beneficial for CF patients, allowing them to maintain their therapy regimen at home, school, or work, thereby enhancing adherence and quality of life. The integration of such devices into daily routines is important for managing a chronic, progressive disease like CF.

Bronchiectasis, characterized by permanent dilation of the bronchi and chronic productive cough, also benefits significantly from OPEP therapy. These patients experience recurrent bacterial infections and inflammation due to impaired mucus clearance. OPEP devices assist in clearing the copious, often purulent, sputum, thereby reducing bacterial load and improving symptoms. Regular OPEP use can decrease the frequency and severity of exacerbations, which are a major cause of morbidity and hospitalizations in this population. The mechanical action of OPEP helps to break the cycle of infection and inflammation that drives disease progression in bronchiectasis. Our previous coverage on new therapies for non-cystic fibrosis bronchiectasis highlights the ongoing efforts to improve outcomes in this challenging disease.

In chronic obstructive pulmonary disease (COPD), particularly in patients with a chronic productive cough phenotype, OPEP therapy can be a valuable adjunct. While bronchodilators and corticosteroids are mainstays of COPD management,

they do not directly address mucus hypersecretion and impaired clearance. OPEP devices can help these patients clear sputum, potentially reducing dyspnea and improving exercise tolerance. The benefit is most pronounced in patients with significant mucus burden, where improved clearance can lead to fewer exacerbations and a better overall respiratory status. But patient selection is important, as not all COPD patients experience significant mucus retention. For patients with severe airflow limitation, the positive pressure generated by OPEP devices may need careful titration to avoid over-distension.

Asthma, especially severe asthma with mucus plugging, can also benefit from OPEP therapy. While bronchodilators and inhaled corticosteroids manage inflammation and bronchoconstriction, mucus plugs can contribute to airway obstruction and poor asthma control. OPEP devices can help dislodge these plugs, improving airflow and potentially reducing the need for rescue medication. This is particularly relevant during acute exacerbations where mucus accumulation can be a major factor in respiratory distress. The role of OPEP in asthma is less universally applied than in CF or bronchiectasis, but it offers a targeted approach for patients whose asthma is complicated by significant mucus hypersecretion. The broader issue of epithelial dysfunction in airway disease highlights the interconnectedness of these conditions.

Integrating OPEP into Clinical Practice

Successful integration of OPEP therapy into routine clinical practice requires a multidisciplinary approach. Respiratory physiotherapists play a critical role in patient education, demonstrating proper technique, and ensuring adherence. Nurses can reinforce instructions and monitor patient progress. Physicians must identify appropriate candidates for OPEP therapy, considering the underlying respiratory condition, the degree of mucus retention, and the patient's ability to perform the technique. Contraindications are few but include untreated pneumothorax, haemoptysis, and severe haemodynamic instability. The cost-effectiveness of OPEP devices, particularly when compared to repeated hospitalizations for exacerbations, makes them an attractive long-term management strategy. The initial investment in a device is often offset by reduced healthcare utilization over time.

Patient education is paramount. Patients must understand the rationale behind OPEP therapy, its benefits, and how to use the device correctly and consistently. Motivation is key for adherence to any long-term therapy, and OPEP is no exception. Providing clear, concise instructions, visual aids, and opportunities for hands-on practice can significantly improve patient engagement. Regular follow-up appointments allow clinicians to assess technique, address any challenges, and reinforce the importance of daily therapy. For patients with complex needs, combining OPEP with other airway clearance techniques, such as exercise or nebulized therapies, may be necessary. The goal is always to tailor the mucus management strategy to the individual patient's needs and preferences, maximizing efficacy while minimizing burden. The ongoing research into inflammatory pathways in COPD continues to highlight the complex relationship of factors contributing to mucus dysfunction.

But OPEP therapy is not a panacea. Its effectiveness relies heavily on patient adherence and correct technique. Patients who are cognitively impaired, severely debilitated, or have significant physical limitations may struggle with consistent use. The devices also require regular cleaning and maintenance to prevent bacterial contamination, a factor that can be overlooked by patients. While generally well-tolerated, some patients may experience transient dyspnea, lightheadedness, or cough during initial use. These side effects are usually mild and resolve with practice and proper technique. The lack of specific, large-scale comparative effectiveness trials against other airway clearance techniques in all populations means that clinical decisions often rely on expert consensus and smaller, disease-specific studies. This

gap matters, particularly when trying to establish the optimal place for OPEP in a crowded therapeutic market. The absence of a single, definitive trial demonstrating superiority across all indications means that clinicians must exercise judgment based on individual patient profiles and existing guideline recommendations.

The future of OPEP therapy likely involves further refinement of device technology, potentially incorporating smart features for adherence monitoring and personalized feedback. Research into optimal oscillation frequencies and pressures for different mucus rheologies could also enhance efficacy. As our understanding of mucus biology and airway inflammation evolves, OPEP therapy will continue to be an important, non-pharmacological tool in the clinician's arsenal for managing chronic respiratory diseases. The next step involves more robust, head-to-head trials to definitively position OPEP within comprehensive airway clearance strategies.

CLINICAL IMPLICATIONS

OPEP therapy offers a pragmatic, low-cost solution for a persistent clinical problem: mucus retention in chronic lung disease. For clinicians, this means another tool in the armamentarium that can be prescribed for home use, potentially reducing the burden on hospital-based physiotherapy services. It empowers patients to take an active role in their own care, which is invaluable for long-term adherence in chronic conditions.

The evidence base, while not always from large, definitive trials, consistently points to OPEP's utility in improving sputum clearance and lung function across conditions like CF and bronchiectasis. It is not a replacement for pharmacological interventions, but an important adjunct for improving patient outcomes. Integrating OPEP into care pathways requires a commitment to patient education and follow-up, ensuring proper technique and sustained use.

But the lack of head-to-head data against other airway clearance methods in some populations means that clinicians still rely on a degree of clinical judgment. We need more rigorous comparative studies to define precisely where OPEP offers the most significant advantage. Until then, it remains a solid, if not universally superior, option for patients struggling with mucus.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Barker AF, Karamooz E. Non-Cystic Fibrosis Bronchiectasis in Adults: A Review. JAMA. 2025;334(3):253-264. doi:10.1001/jama.2025.2680
2. 2. O'Donnell AE. Bronchiectasis - A Clinical Review. N Engl J Med. 2022;387(6):533-545. doi:10.1056/NEJMra2202819
3. 3. Doumat G, Aksamit TR, Kanj AN. Bronchiectasis: A clinical review of inflammation. Respir Med. 2025;244:108179. doi:10.1016/j.rmed.2025.108179
4. 4. Elborn JS, Blasi F, Haworth CS, et al. Bronchiectasis and inhaled tobramycin: A literature review. Respir Med. 2022;192:106728. doi:10.1016/j.rmed.2021.106728
5. 5. Conceição M, Shteinberg M, Goeminne P, Altenburg J, Chalmers JD. Eradication treatment for Pseudomonas aeruginosa infection in adults with bronchiectasis: a systematic review and meta-analysis. Eur Respir Rev. 2024;33(171). doi:10.1183/16000617.0178-2023

6. 6. Gudmundsson G, Juliusson G. [Bronchiectasis - a review]. Laeknabladid. 2020;106(7):352-361. doi:10.17992/lbl.2020.0708.592